Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Teva | Bleomycin | Bleomycin | 1996-06-01 | |||
Docetaxel | Docetaxel | 2015-09-16 | ||||
Docetaxel | Docetaxel Teva | 2010-01-26 | ||||
Docetaxel | Docetaxel Teva Pharma | 2011-01-21 | ||||
Temozolomide | Temozolomide Teva | 2010-01-28 | ||||
Meitheal Pharmaceuticals | Dacarbazine | Dacarbazine | 1998-08-27 | |||
Bleomycin | Bleomycin | 2018-04-20 | ||||
Carmustine | Carmustine | 2021-08-02 | ||||
Dactinomycin | Dactinomycin | 2020-11-13 | ||||
Docetaxel | Docetaxel | 2018-08-24 | ||||
Ingenus | Carmustine | Carmustine | 2022-06-21 | |||
Docetaxel | Docetaxel | 2036-03-14 | 2022-11-22 | |||
Mylan | Docetaxel | Docetaxel | 2023-05-11 | |||
Docetaxel | Docetaxel Mylan | 2012-01-31 | ||||
Carmustine | Carmustine | 2023-03-03 | ||||
Rising Pharmaceuticals | Temozolomide | Temozolomide | 2016-06-29 | |||
Roche | Cobimetinib | Cotellic | 2015-11-20 | $58.637 M | Y2020 | |
Ribavirin, Peginterferon alfa-2a | Pegasys Copegus | 2004-06-04 | ||||
Interferon alfa-2a | Roferon-A | 1986-06-04 | ||||
Vemurafenib | Zelboraf | 2026-06-21 | 2011-08-17 | |||
Atezolizumab | Tecentriq | 2017-09-20 | $4,406.336 M | Q4/22-Q3/23 | ||
Cipla | Bleomycin | Bleomycin | 2019-03-11 | |||
Sandoz | Docetaxel | Docetaxel | 2011-06-29 | |||
Temozolomide | Temozolomide Sandoz | 2010-03-15 | ||||
Novartis | Trametinib | Mekinist | 2014-06-30 | |||
Dabrafenib | Tafinlar | 2025-06-10 | 2013-05-29 | |||
Sanofi | Docetaxel | Taxotere | 1996-05-14 |